Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-Glycoprotein/MDR1 in Caco-2 cells

References

• Buyse, M., Radeva, G., Bado, A., Farinotti, R. (2005). Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 69:1745–1754.
   PubMed Web of Science ®Google Scholar
• Dürr, D., Stieger, B., Kullar-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J., et al. (2000). St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604.
   PubMed Web of Science ®Google Scholar
• Giessmann, T., May, K., Modess, C., Wegner, D., Hecker, U., Zschiesche, M., et al. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192–200.
   PubMed Web of Science ®Google Scholar
• Ho, G. T, Moodie, F. M., Satsangi, J. (2003). Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52:759–766.
   PubMed Web of Science ®Google Scholar
• Kalitsky-Szirtes, J., Shayeganpour, A., Brocks, D. R., Piquette-Miller, M. (2004). Suppression of drug-metabolizing and efflux transporters in the intestines of endotoxin-treated rats. Drug Metab Dispos 32:20–27.
   PubMed Web of Science ®Google Scholar
• Lilja, J. J., Niemi, M., Neuvonen, P. J. (2004). Rifampicin induces plasma concentrations of celiprolol. Eur J Clin Pharmacol 59:819–824.
   PubMed Web of Science ®Google Scholar
• Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Masereeuw, R., Moons, M. M., Russel, F. G. M. (1997). Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur J Pharmacol 321:315–323.
   PubMed Web of Science ®Google Scholar
• Patel, V. A., Dunn, M. J., Sorokin, A. (2002). Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277:38915–38920.
   PubMed Web of Science ®Google Scholar
• Peng, S., Duggan, A. (2005). Gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs. Exp Opin Drug Saf 4:157–169.
   PubMedGoogle Scholar
• Robinson, L. J., Roberts, W. K., Ling, T. T., Lamming, D., Sternberg, S. S., Roepe, P. D. (1997). Human MDR 1 protein overexpressing delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:11169–11178.
   PubMed Web of Science ®Google Scholar
• Ruefli, A. A., Tainton, K. M., Darcy, P. K., Smyth, M. J., Johnstone, R. W. (2005). P-glycoprotein inhibits caspase-8 activation but not formation of death-inducing signal complex (disc) following Fas ligation. Cell Death Differ 9:1266–1272.
   Google Scholar
• Ruth, A. C., Roninson, I. B. (2000). Effects of the multidrug transporter, P-glycoprotein, on cellular responses to ionizing radiation. Cancer Res 60:576–578.
   Google Scholar
• Smyth, M. J., Krasovskis, E., Sutton, V. R., Johnstone, R. W. (1998). The drug-efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 95:7024–7029.
   PubMed Web of Science ®Google Scholar
• Solokin, A. (2004). Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10:647–657.
   PubMed Web of Science ®Google Scholar
• Steffansen, B., Nielsen, C. U., Brodin, B., Eriksson, A. H., Andersen, R., Frokjaer, S. (2004). Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 21:3–16.
   PubMed Web of Science ®Google Scholar
• Takano, M., Yumoto, R., Murakami, T. (2006). Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109:137–161.
   PubMed Web of Science ®Google Scholar
• Takara, K., Tsujimoto, M., Ohnishi, N., Yokoyama, T. (2002). Digoxin upregulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commum 292:190–194.
   PubMed Web of Science ®Google Scholar
• Troutman, M. D., Trakker, D. R. (2003). Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192–1199.
   PubMed Web of Science ®Google Scholar
• Tsuji, M., DuBois, R. N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501.
   PubMed Web of Science ®Google Scholar
• van der Sandt, I. C., Blom-Roosemalen, M. C., de Boer, A. G., Breimer, D. D. (2000). Specificity of doxorubicin versus rhodamin-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1, and Caco-2 cell lines. Eur J Pham Sci 11:207–214.
   PubMed Web of Science ®Google Scholar
• Zatelli, M. C., Luchin, A., Piccin, D., Tagliati, F., Bottoni, A., Vignali, C., et al. (2005). Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90:5754–5760.
   PubMed Web of Science ®Google Scholar
• Ziemann, C., Schafer, D., Rudell, G., Kahl, G. F., Hirsch-Ernst, K. I. (2002). The cyclooxygenase system participates in functional MDR1b overexpression in primary rat hepatocyte cultures. Hepatology 35:579–588.
   PubMed Web of Science ®Google Scholar